^
    Back
    Association details:
    Biomarker:ADAM9 expression
    Cancer:Solid Tumor
    Drug:izeltabart tapatansine (IMGC936) (Microtubule inhibitor, ADAM9-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Estudio del medicamento IMGC936 (primera vez que se prueba en personas) en pacientes con tumores sólidos avanzados

    Excerpt:
    ...Tumor specimens for retrospective determination of ADAM9 expression via IHC staining will be collected from all participants and will be assayed at a central laboratory designated by the sponsor.6. ...
    Trial ID:
    2021-002264-41
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

    Published date:
    05/05/2022
    Excerpt:
    IMGC936 exhibited cytotoxicity toward ADAM9-positive human tumor cell lines, as well as bystander killing, potent antitumor activity in human cell line-derived xenograft and patient-derived xenograft tumor models, and an acceptable safety profile in cynomolgus monkeys...
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-21-0915